Back to results

Massachusetts Institute of Technology

Examining metabolic vulnerabilities for cancer therapy

Abstract

dc:description.abstract

Metabolic reprogramming is essential for cancer cells to balance energetics, maintain redox homeostasis, and synthesize biosynthetic precursors. Many chemotherapeutics that target metabolism are essential components of standard cancer treatment regimens, arguing that there is a therapeutic window to target the metabolic dependencies of cancer cells. However, the use of these drugs as cancer therapies was determined empirically, and rational approaches to directly target the metabolism of cancer cells, especially reprogrammed glucose metabolism, have proved challenging, in part because it is not well understood which metabolic processes are most important for cancer cell proliferation and survival. The goal of this dissertation is to explore metabolic pathways preferentially used by cancer cells in order to identify potential tumor dependencies that could be exploited for clinical benefit. We first determined that production of reactive byproducts is an indirect consequence of the altered glucose metabolism of cancer cells, which suggests that clinically targeting secondary effects of reprogrammed tumor metabolism could be an approach for designing novel cancer treatments. Next, we found that a molecular driver for the altered glucose metabolism of cancer cells is limited electron acceptor availability, suggesting that interventions that further restrict the oxidative capacity of tumors could also have anticancer efficacy. Finally, we interrogated the metabolic fluxes of breast cancers proliferating in different microenvironments and determined that tumors in the brain parenchyma display enhanced lipid biosynthesis, which could guide therapeutic strategies to treat cancer based on tumor site. Collectively, these studies contribute to an understanding of how the reprogrammed metabolism of cancer cells introduces targetable dependencies, with the aim of optimizing cancer therapies.

Degree

thesis:*
Department dc:contributor.department
Massachusetts Institute of Technology. Department of Biology.
Grantor dc:publisher
Massachusetts Institute of Technology
Year dc:date.issued
2018

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Luengo, Alba
Advisor dc:contributor.advisor
  • Matthew G. Vander Heiden.

Subjects

dc:subject × 1

Rights

dc:rights
Statement dc:rights
  • MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission.
Language dc:language.iso
eng

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/1721.1/117787
OAI identifier oai:identifier
oai:dspace.mit.edu:1721.1/117787

Chain of custody

source
Harvested from
MIT
Base URL
dspace.mit.edu/oai/request
Last updated
2026-07-22
Source record
OAI-PMH GetRecord
related terms
citation

Luengo, Alba. Examining metabolic vulnerabilities for cancer therapy. Massachusetts Institute of Technology, 2018. http://hdl.handle.net/1721.1/117787